"Utilization of targeted near-infrared molecular imaging to improve pulmonary metastasectomy of osteosarcomas,"
Background
Osteosarcomas are rare tumors that are typically treated with a combination of surgical resection, chemotherapy, and possibly radiation. 1, 2 Even with this aggressive treatment protocol, distant metastases are common and ultimately result in patient morbidity or death. For a small group of osteosarcoma patients, the lung represents the single site of metastasis. Within this cohort, pulmonary metastasectomy can eliminate all metastatic disease, thus providing an opportunity for long-term survivorship and possible cure. 1, 2 To provide complete pulmonary metastasectomy for patients with osteosarcoma, open approaches have traditionally been utilized, which allows the surgeon to assess for additional lesions by visualization and palpation. Although minimally invasive pulmonary resection provides advantages over open approaches, limited visualization and tactile feedback can make localization of metastases challenging. 3 Several groups have proposed utilizing targeted, near-infrared (NIR) fluorescent contrast agents for real-time intraoperative detection of pulmonary lesions during minimally invasive pulmonary resection. For example, our group has recently reported phase I results involving a NIR folate receptor-α (FRα)-targeted probe, OTL38. 4, 5 In these initial reports, we have found that >90% of primary lung cancers accumulate OTL38 and generate tumor fluorescence during minimally invasive pulmonary resection. In addition to reproducibly detecting nodules as small as 3 mm, this approach has allowed us to find occult cancers in 12% of patients enrolled.
Interestingly, recent evidence suggests that osteosarcomas express a number of unique molecular markers, one of which is the FRα. 6, 7 Given previous first-in-human successes with OTL38 and the growing data suggesting expression of FRα in up to 80% of primary osteosarcomas, we hypothesized that molecular imaging with OTL38 could improve lesion localization during pulmonary metastasectomy for osteosarcoma. In this proof-of-principle case report, we describe the application of fluorescence-guided surgery with OTL38 in a 24-year-old male who presented for resection of an osteosarcoma metastasis to the lung.
Clinical Summary
A 24-year-old male with history of a left humerus osteosarcoma, 4 years status-post resection followed by chemotherapy (doxorubicin and methotrexate), was seen in our multidisciplinary thoracic oncology clinic for evaluation of left lower lobe (LLL) lesion. Preoperative chest CT demonstrated a 1.4-cm nodule in the LLL that was suspicious for a pulmonary metastasis given his history of osteosarcoma [ Fig. 1(a) ]. There were no other nodules appreciated. Given concern for malignancy, he was consented for a wedge resection via video-assisted thoracic surgery (VATS).
After providing informed consent to participate in a study approved by the University of Pennsylvania Institutional Review Board, the subject received intravenous OTL38 (0.025 mg∕kg) 4 h before undergoing VATS resection. During surgery, the known LLL lesion displayed high levels of fluorescence upon in situ NIR imaging with an optimized NIR thoracoscope (Iridium; Visionsense, Philadelphia, Pennsylvania), Both nodules were wedge resected using real-time fluorescence feedback. Of note, in situ tumor-to-background fluorescence ratios of the known LLL lesion and the major fissure lesion were 2.9 and 3.0, respectively.
After histopathologic review, both nodules were confirmed to be osteosarcoma metastases. Upon FRα immunohistochemistry, we appreciated moderate levels of FRα expression within acellular portions of the tumor; however, we observed high levels within the highly cellular portions of the tumor near the margin (Fig. 3) . Using an NIR microscopic scanner (Odyssey, Li-Cor), we confirmed that areas of high FRα expression correlated with highest levels of contrast agent accumulation and fluorescence.
The subject recovered uneventfully without signs of drug toxicity and remains disease free after 1 year of follow-up.
Discussion
In this report, we demonstrate feasibility and utility of NIR molecular imaging using the FRα-targeted agent, OTL38, in a patient undergoing pulmonary metastasectomy for osteosarcoma. In addition to localizing the preoperatively identified nodule, this technology assisted in the identification of an additional 0.4-cm metastasis during minimally invasive pulmonary resection. Similar approaches have been implemented for soft tissue sarcomas; 8, 9 however, this proof-of-principle report supports additional studies exploring this approach for osteosarcomas and potentially other FRα-expressing malignancies. OTL38 is an optical contrast agent consisting of a modified folate molecule (ligand to the FRα), which is linked to an NIR fluorophore; OTL38 excites and emits in the NIR range (λ ex 774 and λ em 795). 10 In our previous work, we have demonstrated that OTL38 binds the folate receptor with a high affinity, thus allowing for identification of synchronous disease in ∼10% of lung cancer patients and reproducible detection of subcentimeter nodules. 4, 5 Based on our initial successes, we have hypothesized that this approach would be applicable to other pulmonary malignancies that express the FRα; however, the presented data herein are the first data to support this principle.
Osteosarcomas metastases to the lung are an excellent disease to explore additional indications for FRα-targeted molecular imaging for several reasons. Most obviously is a lack of alternative intraoperative adjuncts to allow for localization of known lesions and identification of additional disease deposits. As demonstrated in this case, this technology assisted in localization of the known LLL nodule and highlighted a second nodule which was radiographically occult. Next, despite many limitations of thoracotomy (open surgery), many surgeons advocate for thoracotomy during metastasectomy as it theoretically allows for improved visualization and ability to palpate the lung. As we demonstrate here, utilization of OTL38 may provide supplemental information that allows for detection of small or hard to locate nodules during minimally invasive resection.
Interestingly, upon histopathologic review we noted that FRα expression was heterogenous in the fluorescent areas of the tumor. This expression pattern is similar to our observations involving molecular imaging with OTL38 for pulmonary adenocarcinomas, and we have previously noted that tumor fluorescence is present even when as little as 20% to 30% of tumor expresses FRα.
5,11 As we continue enrollment of patients with osteosarcoma metastases in clinical trials, we will better understand how this expression pattern impacts the reproducibility of in vivo tumor fluorescence during pulmonary metastasectomy. Although additional data are required before drawing final conclusions, we find these results encouraging for several reasons. First, the drug was safely delivered and no toxicity was observed. This is consistent with the low toxicity profile reported with other targeted NIR imaging probes. 10, 12 Next, the subcentimeter sensitivity observed suggests that this technology may ultimately enhance oncologic resections by identification of small cancer deposits which are often challenging to locate based on preoperative imaging or by visualization/palpation alone. Finally, utilization of this technology was useful during minimally invasive pulmonary resection (VATS) and thus may provide a real-time, intraoperative adjunct to conventional minimally invasive surgery.
In summary, we present the first human application of molecular imaging for identification of pulmonary metastases for patients with osteosarcoma. We found this approach safe, highly sensitive, and useful during minimally invasive pulmonary resection. In the future, this technology may enhance the surgeon's ability to perform a variety of oncologic procedures, including tumor localization, margin assessment, and intraoperative staging. At this time, we are further evaluating this approach in a phase I clinical trial (NCT02602119).
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